QMQinge Ma

Qinge Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qinge Ma has a total of 173 co-authors. Here are the top co-authors by number of shared publications:

  • Rongrui Wei

    School of Life Science and Technology, College of Medicine and Health Science, Wuhan Polytechnic University, Wuhan, P. R. China

    33 shared publications
  • Rongrui Wei

    College of Medicine and Health Science & School of Life Science and Technology, Wuhan Polytechnic University, Wuhan, China

    14 shared publications
  • Zhipei Sang

    School of Pharmaceutical Sciences, Hainan University, Haikou, China

    13 shared publications
  • Zhi-Pei Sang

    School of Pharmaceutical Sciences, Hainan University

    10 shared publications
  • Zhipei Sang

    Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China

    9 shared publications
  • Rong-Rui Wei

    College of Medicine and Health Science and School of Life Science and Technology, Wuhan Polytechnic University

    7 shared publications

Latest Publications

  • Open Access

    Anti‐Inflammatory Effects of Vicatia thibetica De Boiss. in Rheumatoid Arthritis and Associated Multi‐Pathway Modulation In Vivo

    by Mo‐Zi‐Li Adu, Wei Jiang, Min Li, Bo‐Wei Xia, En Yuan, Yue‐Zhi Tan, Wu‐Xin Yang, Guo‐Yue Zhong, Qin‐Ge Ma, Rong‐Rui Wei

    Vicatia thibetica de Boiss. (VTDB) is not only used as an important Tibetan medicine but is also consumed as a common wild vegetable. Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation and progressive destruction of cartilage and bone. VTDB is recorded in the Four Medical Classics for treating “Huang‐Shui,” a condition resembling RA. To preliminarily investigate its potential therapeutic basis, VTDB and its polarity‐based fractions were evaluated for their effects against RA. The chemical constituents of VTDB‐TE were profiled using UHPLC‐Q‐Orbitrap MS/MS, and network pharmacology analysis predicted possible involvement of the PI3K/Akt and JAK2/STAT3 signaling pathways. Among the tested fractions, VTDB‐nBuOH exhibited the most pronounced pharmacological activity in the collagen‐induced arthritis (CIA) rat model. VTDB‐nBuOH treatment was associated with reduced paw swelling, lower serum levels of rheumatoid factor (RF) and C‐reactive protein (CRP), and improved synovial histopathology. The treatment was also associated with reduced levels of pro‐inflammatory cytokines and alterations in the levels of proteins associated with PI3K/Akt, JAK2/STAT3, and the downstream IKK/IκB/NF‐κB axis. Additionally, VTDB‐nBuOH treatment was associated with a shift in macrophage polarization markers toward an anti‐inflammatory M2‐like phenotype, suggesting a possible restoration of the M1/M2 balance within the joint microenvironment. 16S rRNA sequencing revealed VTDB‐nBuOH treatment‐associated changes in gut microbial composition, including enrichment of certain beneficial genera and reduction of some pathogenic taxa. Proteomic analysis also pointed to the PI3K/Akt pathway as a potential node of interest. Collectively, these correlative findings suggest that VTDB‐nBuOH may alleviate synovial inflammation and cartilage and bone damage through multi‐pathway modulation, though further mechanistic studies are needed to establish causality. VTDB‐nBuOH shows preliminary promise for further investigation as a potential candidate for RA treatment.

  • Botany, extraction methods, chemical constituents, pharmacological activities, and food applications of Stauntonia chinensis

    by Chen-Yu Chang, Xiao-Yun Wang, Ke-Jia Liu, Qi Li, Shu-Yan Lu, Qin-Ge Ma, Rong-Rui Wei

    1. Stauntonia chinensis DC. (Lardizabalaceae) is the only officially recognised botanical source for the Chinese herb “Yemugua” in the 2025 edition of the Pharmacopoeia of the People’s Republic of ...

  • Structurally Diverse Analgesic Phenylpropanoid Glycosides from Stauntonia chinensis

    by Jia-Wei Pan, Kai-Bo Chem, Jiang-Mei Wu, Hong Xu, Rui-Ze Chen, Hai Hu, Wen-Min Liu, Yan Zheng, Rong-Rui Wei, Qin-Ge Ma

  • Open Access

    Editorial: Prevention and treatment of metabolic diseases using bioactive metabolites of herbal medicines also used as foods

    by Rong-Rui Wei, Wen-Min Liu, Chun-Su Yuan, Chun-Lei Zhang, Zhi-Pei Sang, Qin-Ge Ma

    Liver disease is a general term for lesions that occur in the liver. Its pathogenesis is complex and mainly related to factors such as viral infection, metabolic abnormalities, drug effects, and alcohol intake (Zhong et al., 2025). These factors can lead to liver cell damage, inflammatory response, and fibrosis process (Bai et al., 2025). The main classifications of liver diseases include NAFLD, drug-induced liver injury, viral hepatitis, and liver cancer (Ma et al., 2025). The liver disease is extremely harmful, with hidden early symptoms and the possibility of developing into cirrhosis, liver failure, and even liver cancer in the later stages. This disease seriously endangers human health (Xiao et al., 2025). The current treatment of liver disease has made certain progress, and the combination of immunotherapy and targeted therapy for liver cancer significantly prolongs the survival of patients. The approval of the first MASH targeted drug marks a new stage in the treatment of metabolic liver disease, but there are still limitations (Ali and Lai, 2025). Antiviral drugs used to treat liver disease have a risk of drug resistance and a high recurrence rate after discontinuation. Some drugs used to treat liver diseases have high prices, drug resistance risks, and side effects (McNally and Carey, 2025). However, traditional Chinese medicine with the same origin of medicine and food has shown unique advantages in the treatment of liver disease (Ma et al., 2023). These natural medicines can regulate liver metabolism and reduce inflammatory reactions through multiple targets. It also has minimal side effects and is suitable for long-term regulation. It can effectively assist in improving liver function (Ma et al., 2024). In the future, the treatment of liver diseases will develop towards precision, intelligence, and minimally invasive methods (Ghosh et al., 2025). Gene editing, regenerative medicine, and other technologies are expected to break through existing treatment bottlenecks (Nair et al., 2025). Digitized liver resection technology and multidisciplinary integrated diagnosis and treatment models will further enhance treatment effectiveness, bringing new hope to liver disease patients.Xu et al. evaluated the effects of rhein on inflammation, renal function, and gut microbiota induced by high-fat diet in C57BL/6J mice. The mice were fed a 60% fat diet for 12 weeks to establish an obesity related glomerular model. After continuous feeding of rhein (300 mg/kg/day) for 12 weeks, serum cytokines (IL-6, TNF-α), renal tissue pathology, and 16S rRNA microbiome sequencing were measured and analyzed. The research results indicated that rhein significantly reduced body weight, serum triglycerides, proteinuria, and improved glomerular lesions in mice, and it also significantly reduced the levels of serum IL-6, TNF-α, and creatinine. It was found that rhein restored the diversity of gut microbiota (Chao1 index increased from 303.58 to 425.78) and reversed the imbalance between Firmicutes and Bacteroidetes through 16S rRNA sequencing. The study found that significant differences in microbial community structure (between the rhein group and the model group) were confirmed through similarity analysis (R=0.926, p=0.008). In a word, rhein occasionally alleviated the progression of obesity-related glomerulopathy, and confirmed that this was related to factors such as anti-inflammatory, lipid-lowering, and microbial community regulation mechanisms.Li et al. used LC-MS, computer simulation docking analysis, and molecular dynamics to study the inhibition of cytochrome P450 enzymes by triterpenoids of Ganoderma lucidum, and evaluated their interference with clinical drug metabolism processes. It was found that triterpenoids of Ganoderma lucidum inhibited multiple CYP450 subtypes and interfered with the pharmacokinetics of some drugs in rats.This study also evaluated the inhibitory effects of triterpenoids on CYP 1A2, 2D6, 3A4, 2A6, 2B6, 2C9, and 2C19. The results showed that lanostane triterpenoids significantly inhibited CYP 1A2, indicating a strong affinity for these compounds. It was also found that some triterpenoids of Ganoderma lucidum only showed extensive inhibitory effects on CYPs, except for CYP 3A4, 2D6, 2C9, and 2C19. In addition, LC-MS, computer simulation docking analysis, and molecular dynamics studies displayed that some triterpenoids of Ganoderma lucidum interfered with clinical metabolism by inhibiting CYPs in vitro, which probably induced potential drug interactions. The above research provides important reference value for the promotion of human health by triterpenoids of Ganoderma lucidum. Targeted serum metabolomics studies were conducted using UHPLC-LTQ Orbitrap MS in this work, and 16S rRNA analysis was employed to elucidate the mechanisms by regulating lipid and glucose metabolism. It was found that phenylpropanoids of Zea mays L. significantly reduced oral glucose tolerance test values, insulin, and blood glucose levels at a dose of 160 mg/kg/day (P < 0.001). The phenylpropanoids of Zea mays L. lowered the insulin resistance index, reversed the accumulation of glycogen in the liver, and reduced lipid deposition in the liver. The 16S rRNA sequencing results indicated that phenylpropanoids of Zea mays L. interacted with gut microbiota, exerting a positive regulatory effect on bifidobacteria, and lactobacilli.Therefore, phenylpropanoids of Zea mays L. have great potential as adjuvant therapy for complex metabolic diseases such as diabetes.Leonardo et al. found that Delites™ prevented metabolic syndrome in male SD rats induced by high cholesterol and high-fat diet, and regulated their gut microbiota in a randomized preclinical trial. Delites™ is a supplement closely related to traditional Chinese medicine, which holds potential development value in regulating intestinal microbiota and alleviating metabolic syndrome. In this study, SD rats were divided into 4...


  • Phenylpropanoid-homoisoflavonoid derivatives from the fruits of Hippophae rhamnoides L. and their hepatoprotective and hypolipidemic activities

    by Qin-Ge Ma, Yan-Li Shi, Qi Li, Xin Chen, Liang Liu, Wen-Min Liu, Rong-Rui Wei

    Hippophae rhamnoides L. is an edible fruit for both medicine and food. Twelve new phenylpropanoid-homoisoflavonoid derivatives were isolated from this plant. Compounds (3–5, 7–9) exhibited hepatoprotective and hypolipidemic activities, respectively.


  • Open Access

    Editorial: Preventing and treating liver diseases: medicinal and food plants, their metabolites as potential options

    by Rongrui Wei, Wenmin Liu, Chunsu Yuan, Chunlei Zhang, Zhipei Sang, Qinge Ma

    Liver disease is seriously endangering human health in the world. It has become the leading cause of death in the word (Israelsen et al., 2024). The presence and progression of liver fibrosis led by hepatic inflammation is the main predictor of liver-related death across the entire spectrum of steatotic liver diseases (Taru et al., 2024). A combination of recent advancements of widely available biomarkers for early detection of liver fibrosis together with considerable advancements in therapeutic interventions offer the possibility to reduce morbidity and mortality in patients with liver disease (Dabrowska et al., 2024). Thus, it is urgent to find safe and effective drugs to treat liver diseases. The medicinal and food plants have unique advantages in terms of safety and compliance, which have always been an important source for finding new hepatoprotective drugs (Xu et al., 2024). Consequently, the discovery of new hepatoprotective natural products from medicinal and food plants is of great practical significance for the development of new hepatoprotective drugs, which has the advantages of safety, multi-targets, and multi-pathways. We are deeply privileged to compile this research topic of Frontiers in Pharmacology dedicated to "preventing and treating liver diseases: medicinal and food plants, their metabolites as potential options".The study by Han et al. discussed about the effects of a low-dose (0.6 g/kg) and high-dose (1.2 g/kg) of zhuyu pill on a cholestasis rat model induced by naphthyl isothiocyanate (50 mg/kg). In this study, serum biochemistry and histopathology results were used to evaluate the therapeutic effect of zhuyu pill, and mRNA-Seq analysis was performed and verified using real-time uorescence quantitative PCR.The GO, KEGG, and GSEA analyses were integrated to identify the mechanism by which Zhuyu pill impacted cholestatic rats.It was found that zhuyu pill significantly improved abnormal changes in the biochemical blood indexes and liver histopathology of cholestasis rats, regulated pathways related to bile and lipid metabolism, including fatty acid metabolism, retinol metabolism, and steroid hormone biosynthesis, and alleviated inflammation, cholestasis, and lipid metabolism disorders.Relative expression of the essential genes Cyp2a1, Ephx2, Acox2, Cyp1a2, Cyp2c11, and Sult2a1 was verified by qRT-PCR and showed the same trend as mRNA-seq analysis (Han et al., 2023). Therefore, zhuyu pill has a significant anti-cholestatic effect by regulating bile metabolism and lipid metabolism related pathways. These findings indicate that zhuyu pill is a novel and promising prospect for treating cholestasis.Rutaecarpine is a natural pentacyclic indolopyridoquinazolinone alkaloid, which is isolated from Evodia rutaecarpa for the first time. It is used for treating a variety of ailments, including headaches, gastrointestinal disorders, postpartum hemorrhage, amenorrhea, difficult menstruation, and other diseases. Li et al. made a comprehensive description of Rutaecarpine derivatives by focusing on their diverse biological activities. In this review, the modification of Rutaecarpine aimed at seeking its derivatives with better physicochemical properties and more potency had been extensively studied. These derivatives exhibited diverse pharmacological activities, including anti-inflammatory, anti-atherogenic, anti-Alzheimer's disease, anti-tumor, and anti-fungal activities via a variety of mechanisms, such as inhibiting cyclooxygenase-2, acetylcholine, phosphodiesterase 4B, phosphodiesterase 5, or topoisomerases (Li et al., 2023). This review gave an insight into the biological activities of Rutaecarpine derivatives and encourage further exploration of Rutaecarpine.Nawaz et al. reviewed therapeutic approaches for chronic hepatitis C. In this review, he critically assesseed the landscape of hepatitis C virus treatment, drawing parallels between traditional interferon/ribavirin therapy historically pivotal in hepatitis C virus management and herbal approaches rooted in traditional and complementary medicine. This review made a comprehensive understanding of the diverse hepatitis C virus genome, its natural variations, pathogenesis, and the impact of dietary, social, environmental, and economic factors (Nawaz et al., 2024). This review primarily focused on the intricate nature of hepatitis C virus genomes and explored the potential of botanical drugs in both preventing and treating hepatitis C virus infections.Feng et al. used meta-analysis to search relevant preclinical references from multiple databases. Statistical analysis was conducted using STATA, which included the use of 3D maps and radar charts to display the effects of matrine dosage and frequency on hepatoprotection and hepatotoxicity. The results demonstrated that matrine had bidirectional effects on ALT and AST levels, and it also regulated SOD, MDA, TG, TC, IL-6, TNF-α, and CAT levels. Based on comprehensive three-dimensional analysis, the optimal bidirectional effective dosage of matrine ranged from 10 to 69.1 mg/kg. However, it demonstrated high liver protection and low toxicity at a dose of 20-30 mg/kg/d for 0.02-0.86 weeks. The molecular docking analysis revealed the interaction between MT and SERCA as well as SREBP-SCAP complexes. Matrine could alter Ca 2+ homeostasis in liver injury via multiple pathways, including the SREBP1c/SCAP, Notch/RBP-J/HES1, IκK/NF-κB, and Cul3/Rbx1/Keap1/Nrf2 (Feng et al., 2024).The pericarp of Herpetospermum pedunculosum has traditionally been used for treating jaundice and hepatitis. Liu et al. characterized the total cucurbitacins extracted from H. pedunculosum and evaluated their hepatoprotective potential.Molecular networking based on UHPLC-MS/MS identified cucurbitacin B, isocucurbitacin B, and cucurbitacin E as the major components in total cucurbitacins, comprising 70.3%, 26.1%, and 3.6% as determined by RP-HPLC, respectively. Total cucurbitacins treatment...


  • Open Access

    Structurally Diverse Quinoline Alkaloids With Antileukaemia Activities From Taraxacum mongolicum

    by Xiaodong Zhang, Qinge Ma, Weiwei Yan, Meng Li, Haixia Liu, Bo Yuan, Xiaoxue Wang

    Taraxacum mongolicum , a medicinal and food homologous traditional Chinese medicine, has important research value in clinical practice. Eight new quinoline alkaloids ( 1 – 8 ), including 1N‐geranyl quinoline alkaloids ( 1 – 3 ), 3,4‐phenylquinoline alkaloids ( 4 – 6 ) and 10‐carbonyl‐11‐pyrrolyl quinoline alkaloids ( 7 – 8) , and twelve known quinoline alkaloid derivatives ( 9 – 20 ) were isolated from T. mongolicum for the first time. These compounds were elucidated according to analysing NMR, MS, UV and IR spectra and compared with references. Among them, compounds ( 7 , 8 , 14 and 16 ) showed certain antileukaemia activities, which exhibited important cell growth inhibitory activities against HL‐60 and K562 cells than adriamycin, which could be potential antileukaemia agents. The plausible biogenetic pathway and preliminary structure–activity relationship of the selected compounds were scientifically summarised and discussed in this work.